Xenetic Biosciences, Inc. — Q1 2018 Form 10-Q
Reporting period: Three months ended March 31, 2018; filed May 15, 2018. Xenetic is a clinical-stage biopharmaceutical company developing oncology therapeutics and biologic-drug technologies. Its lead candidate, XBIO-101, is in a Phase 2 trial for progestin-resistant endometrial cancer; the first patient was dosed in October 2017. PolyXen is its polymer-based drug-enabling platform.
Financial results and liquidity
| Metric | Q1 2018 | Q1 2017 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $706,271 | $1,221,144; down 42.2% |
| General and administrative expense | $1,122,072 | $1,634,533; down 31.4% |
| Operating loss | $1,828,343 | $2,855,677 |
| Net loss | $1,822,518 | $2,865,621 |
| Basic and diluted loss per share | $0.21 | $0.34 |
| Operating cash flow | Used $1,666,803 | Provided $280,809 |
No revenue was recognized from collaboration agreements, and gross margin is not applicable to the reported period. At March 31, 2018, cash was $3.87 million and restricted cash was $66,510, compared with cash of $5.53 million at December 31, 2017. Working capital was approximately $2.5 million, down from $3.9 million at year-end. Current liabilities were $1.74 million; total liabilities were $4.66 million, including a $2.92 million deferred tax liability. The filing does not identify material borrowings or provide a clear debt balance. No cash was provided by financing activities in either comparative quarter.
Changes and management commentary
- Operating and net losses narrowed year over year as R&D and G&A spending fell. Management attributed lower R&D expense to reduced outside research and clinical services, lower personnel costs, and limiting internal development largely to XBIO-101 because of capital constraints. G&A reductions reflected lower employee-related and discretionary costs.
- Q1 2017 operating cash flow included a $3.0 million Shire clinical milestone receipt. Q1 2018 cash use primarily reflected operating costs and XBIO-101 Phase 2 trial initiation expenses.
- Management estimated existing resources would fund planned operations, obligations, and commitments only into Q3 2018. Additional capital or strategic alternatives were needed in the very near term; no financing commitment had been secured.
- The company reported substantial doubt about its ability to continue as a going concern. Without timely financing, it could reduce or suspend development and clinical work, cut expenses, relinquish asset rights, restructure, or cease operations.
- Management continues to seek out-licensing arrangements, including for PolyXen and ErepoXen, but could not reliably predict if or when an agreement would be reached. More than 90% of milestone and sublicense revenue received to date came from Shire.
Outlook, risks, and other items
The filing provides no numerical revenue or earnings guidance. Xenetic expects continued losses and significant R&D investment, subject to available capital. Key risks include the need to raise funds, clinical and regulatory uncertainty, ability to secure collaboration or licensing payments, and dependence on external financing and collaborators. Pharmsynthez is the company’s controlling stockholder; the filing describes research, development, licensing, and supply arrangements with related parties. No material legal proceedings, material changes to previously disclosed risk factors, or subsequent events requiring disclosure were reported. Disclosure controls were considered effective at a reasonable assurance level, with no material change in internal control reported.
Key facts for investors to verify
- Whether Xenetic obtained financing or a strategic transaction after the filing, and whether the stated Q3 2018 cash runway changed.
- Current cash, working capital, and cash burn, including the timing and cost of XBIO-101 clinical development.
- Progress, enrollment, and results of the XBIO-101 Phase 2 trial, as well as regulatory milestones.
- Whether out-licensing or collaboration agreements generated new funding, and the extent of continuing reliance on Shire and related parties.
- Potential dilution from financing: 3,522,225 warrants were outstanding at a weighted-average exercise price of $4.30; verify current warrant and share counts.